Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03523637
Other study ID # PY18/100386
Secondary ID IRAS Project ID:
Status Recruiting
Phase N/A
First received
Last updated
Start date March 5, 2018
Est. completion date September 30, 2018

Study information

Verified date May 2018
Source University of Leeds
Contact Aleksandra Puchala
Phone 07925549965
Email umapu@leeds.ac.uk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to investigate the use of Interoceptive Exposure (IE) in treatment of disabling fear of pain using a single-case series design.


Description:

The intervention Interoceptive Exposure (IE) is an exposure to bodily sensations used in treatment of variety of problems where body sensations are experienced as threatening. The application of IE is expected to reduce the threat value of pain and subsequently promote recovery. This study will evaluate the effects of IE and will briefly comprises of: education session explaining the rationale behind IE practice, teaching of the technique, supervised IE practice and self-monitored home practice twice daily for the period of two weeks. Depending on the length of baseline (i.e. observation period before the start of intervention) the study will last between 6 and 8 weeks. Daily Diary, a short nine item instrument was designed to measure the pain experience (intensity and interference) and fear of pain on a daily basis. Other, standard outcome measures include: pain related anxiety, pain catastrophising, pain related disability, knowledge about pain and general anxiety and depression. Study participants will be recruited during routine psychology screening assessment at the Pain Clinic at St James' Hospital. This study will recruit from clinical psychology waiting list patients.


Recruitment information / eligibility

Status Recruiting
Enrollment 8
Est. completion date September 30, 2018
Est. primary completion date September 30, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Presence of chronic pain (i.e. pain present for minimum of 3 months following tissue damage)

- 18 years or older

- Capacity to give informed consent

- Appropriate diagnostic investigations in other specialties as appropriate have been exhausted and first line interventions, like analgesia, have been tried.

- Participant has appropriate expectations regarding psychological treatment, i.e. does not expect injections etc.

Exclusion Criteria:

- Insufficient understanding of English or additional needs which mean the potential participant is unable to complete questionnaires independently. This is because the research project does not have the resources to make significant adaptations to the materials i.e. translation into another language or into Braille.

- Unable to meet the demands of the study (i.e. daily recording of data, daily practice of IE, coming for sessions to St James' Hospital).

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Interoceptive Exposure
The intervention Interoceptive Exposure (IE) is an exposure to bodily sensations used in treatment of variety of problems where body sensations are experienced as threatening. This psychological technique is about focusing attention on pain, 'staying with the pain' without trying to escape it.

Locations

Country Name City State
United Kingdom Pain Clinic, Fielding House at St James's Hospital Leeds West Yorkshire

Sponsors (1)

Lead Sponsor Collaborator
University of Leeds

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Daily Diary The Daily Diary is a 9 item questionnaire used for recording daily ratings of pain distress, pain interference and the fear of pain. Items 1-4 use visual analogue scales (VAS) to measure pain distress and interference. Each VAS has two anchors: "not at all distressing" and "extremely distressing" for pain distress questions (Items 1-3) and "does not interfere" and "interferes completely" for pain interference (Item 4), providing a range of scores between 0 and 100. Higher scores indicate greater pain distress and interference. Additionally, there are 5 statements assessing the fear of pain, which participants rate on a 5 point Likert Scale, where the score of 0 equals "not at all" and score of 4 equals "all the time". An example question: "Pain Sensations are terrifying". Total Fear of Pain Score is calculated by adding up scores on items 5 to 9. Higher Scores indicate higher fear of pain, min = 0, max = 20. Assessed daily, throughout the duration of the study. Depending on the length of the baseline this will be between 42 and 56 days.
Primary Change in Activity levels, i.e. number of steps taken This will be measured with an activity monitor NOKIA GO worn by participants on their wrists or attached to their belt. Assessed daily, throughout the duration of the study. Depending on the length of the baseline this will be between 42 and 56 days.
Secondary Pain Catastrophising Scale (PCS: Sullivan, Bishop & Pivik, 1995) Standardised measure of pain catastrophising. The PCS is a 13 item scale, with each item rated on a 5-point Likert type scale: 0 (Not at all) to 4 (all the time). Sample item: "I worry all the time about whether the pain will end". The PCS is broken into three sub-scales: magnification, rumination, and helplessness. Scores are added up for each sub-scale, a Total Score is achieved by adding up all 13 items. The higher the score, the more catastrophizing thoughts are present. Previous studies have shown a cutoff of more than 30 points to be associated with clinical relevance. at three time points: assessment (day one), pre-intervention (depending on the length of the baseline 2 weeks, 3 weeks or 4 weeks later) and post-intervention (6, 7 or 8 weeks from the start of the intervention).
Secondary Pain Anxiety Symptoms Scale Short Scale (PASS-20: McCracken & Dhingra, 2002) The PASS-20 assesses pain specific anxiety symptoms using four components of pain-related anxiety: cognitive, fear, escape avoidance, and physiological. Each of the four sub-scales has five items. All items are rated from 0 (never) to 5 (always). Sample item: "I worry when I am in pain". Scores are added up for each sub-scale, a Total Score is achieved by adding up all 20 items. The higher the score, the more pain anxiety symptoms. Maximum Total Score: 100, Minimum Total Score: 0. at three time points: assessment (day one), pre-intervention (depending on the length of the baseline 2 weeks, 3 weeks or 4 weeks later) and post-intervention (6, 7 or 8 weeks from the start of the intervention).
Secondary Pain Disability Index (PDI: Pollard, 1984) This is a brief self-report measure of disability and is designed to measure the extent to which chronic pain interferes with an individual's ability to engage in activities (Pollard, 1981). Respondents rate the degree to which pain interferes with functioning in seven broad areas: family/home responsibilities, recreation, social activity, occupation, sexual behaviour, self-care, and life-support activity on a ten-point scale of 0 (no disability) to 10 (total disability). Sample Item: "Recreation: This disability includes hobbies, sports, and other similar leisure time activities". An overall score (with a possible total of 70) is computed by summing the seven sub-scales, higher scores indicate greater level of pain related disability. Validity and reliability have been established for this measure (Tait, Chibnall and Krause, 1990). at three time points: assessment (day one), pre-intervention (depending on the length of the baseline 2 weeks, 3 weeks or 4 weeks later) and post-intervention (6, 7 or 8 weeks from the start of the intervention).
Secondary Hospital Anxiety and Depression Scale (HADS: Zigmond & Snaith, 1983) Standardised questionnaire used in assessing generalised anxiety and depression. The questionnaire comprises seven questions for anxiety and seven questions for depression (total number of items = 14). Each item on the questionnaire is scored from 0 - 3 and this means that a person can score between 0 and 21 for either anxiety or depression. Sample Item: "I feel tense or 'wound up'", response options: "Most of the time" (scored 3 points), "A lot of the time" (Scored 2 points), "From time to time" (Scored 1 point), "Not at all" (Scored 0 points). Although the anxiety and depression questions are interspersed within the questionnaire, they can be added up together (Total Score) or added up within each sub-scale (Depression Total Score and Anxiety Total Score). Higher scores are indicative of more symptoms of Generalised Anxiety and Depression. at three time points: assessment (day one), pre-intervention (depending on the length of the baseline 2 weeks, 3 weeks or 4 weeks later) and post-intervention (6, 7 or 8 weeks from the start of the intervention).
Secondary Chronic Pain Acceptance Questionnaire (CPAQ: McCracken, Vowles & Eccleston, 2004) Standardised questionnaire used in assessing the acceptance of pain in chronic pain sufferers. The CPAQ assesses acceptance of pain using two factors: Activity Engagement (participation in daily activities while acknowledging the presence of pain, 11 items) and Pain Willingness (the degree to which pain is allowed in experience without efforts to avoid or control it; 9 items). Sample Item: "My life is going well, even though I have chronic pain". The items on the CPAQ are rated on a 7-point scale from 0 (never true) to 6 (always true). Scoring is done by adding the items for Activity engagement and Pain willingness to obtain a Total Score for each factor. Additionally, a total score of Pain Acceptance is calculated by adding the scores for each factor together. Higher scores indicate higher levels of acceptance. Maximum Total Acceptance Score is 120, Minimum Total Acceptance Score is 0. at three time points: assessment (day one), pre-intervention (depending on the length of the baseline 2 weeks, 3 weeks or 4 weeks later) and post-intervention (6, 7 or 8 weeks from the start of the intervention).
See also
  Status Clinical Trial Phase
Completed NCT01659073 - Using Perfusion MRI to Measure the Dynamic Changes in Neural Activation Associated With Caloric Vestibular Stimulation N/A
Recruiting NCT05914311 - Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration N/A
Recruiting NCT05422456 - The Turkish Version of Functional Disability Inventory
Enrolling by invitation NCT05422443 - The Turkish Version of Pain Coping Questionnaire
Completed NCT05057988 - Virtual Empowered Relief for Chronic Pain N/A
Completed NCT04385030 - Neurostimulation and Mirror Therapy in Traumatic Brachial Plexus Injury N/A
Recruiting NCT06206252 - Can Medical Cannabis Affect Opioid Use?
Completed NCT05103319 - Simultaneous Application of Ketamine and Lidocaine During an Ambulatory Infusion Therapy as a Treatment Option in Refractory Chronic Pain Conditions
Completed NCT03687762 - Back on Track to Healthy Living Study N/A
Completed NCT04171336 - Animal-assisted Therapy for Children and Adolescents With Chronic Pain N/A
Completed NCT03179475 - Targin® for Chronic Pain Management in Patients With Spinal Cord Injury Phase 4
Completed NCT03418129 - Neuromodulatory Treatments for Pain Management in TBI N/A
Completed NCT03268551 - MEMO-Medical Marijuana and Opioids Study
Recruiting NCT06060028 - The Power of Touch. Non-Invasive C-Tactile Stimulation for Chronic Osteoarthritis Pain N/A
Recruiting NCT06204627 - TDCS* and Laterality Trainnning in Patients With Chronic Neck Pain N/A
Completed NCT05496205 - A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers Phase 1
Completed NCT00983385 - Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics Phase 3
Recruiting NCT05118204 - Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization Phase 4
Terminated NCT03538444 - Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder N/A
Not yet recruiting NCT05812703 - Biometrics and Self-reported Health Changes in Adults Receiving Behavioral Treatments for Chronic Pain